Last updated on March 2018

A clinical trial seeking patients for a research study of Vemurafenib, Cetuximab, Pertuzumab, Bevacizumab, FOLFOX induction regimen, Trastuzumab, Cobimetinib, Atezolizumab, Fluoropyrimidine (5-FU/LV or capecitabine), 5-FU/LV

Brief description of study

This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have received any prior chemotherapy in the metastatic setting. The entire study duration is anticipated to be approximately 7.5 years.

Clinical Study Identifier: NCT02291289

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: MO29112 ...

DRK Kliniken Berlin K penick Darmzentrum
Berlin, Germany
  Connect »